Oncotarget

Research Papers:

Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer

Liancheng Zhu, Huiyu Zhuang, Huimin Wang, Mingzi Tan, Carlton L. Schwab, Lu Deng, Jian Gao, Yingying Hao, Xiao Li, Song Gao, Juanjuan Liu and Bei Lin _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:729-744. https://doi.org/10.18632/oncotarget.6327

Metrics: PDF 2555 views  |   HTML 3889 views  |   ?  


Abstract

Liancheng Zhu1,*, Huiyu Zhuang1,2,*, Huimin Wang1, Mingzi Tan1, Carlton L. Schwab3, Lu Deng1, Jian Gao1, Yingying Hao1, Xiao Li1, Song Gao1, Juanjuan Liu1, Bei Lin1

1Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning 110004, China

2Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100043, China

3Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut 06520–8063, USA

*These authors have contributed equally to this work

Correspondence to:

Bei Lin, e-mail: [email protected]

Keywords: HE4, epithelial ovarian cancer, proliferation, invasion, metastasis

Received: July 14, 2015     Accepted: October 30, 2015     Published: November 09, 2015

ABSTRACT

Overexpression of Human epididymis protein 4 (HE4) related with a role in ovarian cancer tumorigenesis while little is known about the molecular mechanism alteration by HE4 up regulation. Here we reported that overexpressed HE4 promoted ovarian cancer cells proliferation, invasion and metastasis. Furthermore, human whole genome gene expression profile microarrays revealed that 231 differentially expressed genes (DEGs) were altered in response to HE4, in which MAPK signaling, ECM receptor, cell cycle, steroid biosynthesis pathways were involved. The findings suggested that overexpressed HE4 played an important role in ovarian cancer progression and metastasis and that HE4 has the potential to serve as a novel therapeutic target for ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6327